News >

Personalized Medicine Progressing in Premenopausal Breast Cancer

Caroline Seymour
Published: Wednesday, Apr 17, 2019

Joyce A. O’Shaughnessy, MD

Joyce A. O’Shaughnessy, MD

Eight-year follow-up findings from the TEXT and SOFT trials provided considerable insight into the use of adjuvant endocrine therapy for women with premenopausal hormone receptor (HR)–positive breast cancer, said Joyce A. O’Shaughnessy, MD. However, more follow-up is needed to fully understand how stopping therapy at 5 years will impact disease-free survival (DFS).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x